ECSP10010175A - Productos quimioterapéuticos cristalinos - Google Patents

Productos quimioterapéuticos cristalinos

Info

Publication number
ECSP10010175A
ECSP10010175A EC2010010175A ECSP10010175A ECSP10010175A EC SP10010175 A ECSP10010175 A EC SP10010175A EC 2010010175 A EC2010010175 A EC 2010010175A EC SP10010175 A ECSP10010175 A EC SP10010175A EC SP10010175 A ECSP10010175 A EC SP10010175A
Authority
EC
Ecuador
Prior art keywords
crystal
chemotherapeutic products
chemotherapeutic
products
indazol
Prior art date
Application number
EC2010010175A
Other languages
English (en)
Inventor
Thomas B Borchardt
Alexander Chu-Kung
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ECSP10010175A publication Critical patent/ECSP10010175A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

Forma cristalina 2 de N-(4-(3-amino-1H-indazol-4-il)fenil)-N´-(2-fluoro-5-metilfenil)urea, maneras para elaborarla, formulaciones que comprenden a la misma y elaboradas con la misma y métodos de tratamiento para pacientes que padecen una enfermedad para usarla.
EC2010010175A 2007-10-19 2010-05-14 Productos quimioterapéuticos cristalinos ECSP10010175A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98126507P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
ECSP10010175A true ECSP10010175A (es) 2010-06-29

Family

ID=40174735

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010175A ECSP10010175A (es) 2007-10-19 2010-05-14 Productos quimioterapéuticos cristalinos

Country Status (19)

Country Link
US (1) US7772404B2 (es)
EP (1) EP2195299A1 (es)
JP (1) JP2011500708A (es)
KR (1) KR20100084665A (es)
CN (1) CN101827825B (es)
AU (1) AU2008312534A1 (es)
BR (1) BRPI0818337A2 (es)
CA (1) CA2699356A1 (es)
CO (1) CO6270221A2 (es)
CR (1) CR11444A (es)
DO (1) DOP2010000111A (es)
EC (1) ECSP10010175A (es)
GT (1) GT201000099A (es)
MX (1) MX2010004287A (es)
PA (1) PA8800401A1 (es)
RU (1) RU2010119920A (es)
UA (1) UA99490C2 (es)
WO (1) WO2009052231A1 (es)
ZA (1) ZA201002094B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
AU2015301054B2 (en) 2014-08-08 2020-05-14 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE469888T1 (de) * 2003-05-22 2010-06-15 Abbott Lab Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (ja) * 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
KR20090094815A (ko) * 2006-11-09 2009-09-08 애보트 게엠베하 운트 콤파니 카게 티로신 키나아제 억제제의 경구 투여를 위한 약제 투여형

Also Published As

Publication number Publication date
GT201000099A (es) 2012-03-26
CO6270221A2 (es) 2011-04-20
CA2699356A1 (en) 2009-04-23
AU2008312534A1 (en) 2009-04-23
EP2195299A1 (en) 2010-06-16
UA99490C2 (en) 2012-08-27
WO2009052231A1 (en) 2009-04-23
KR20100084665A (ko) 2010-07-27
MX2010004287A (es) 2010-04-30
CN101827825A (zh) 2010-09-08
CR11444A (es) 2010-10-05
DOP2010000111A (es) 2010-07-15
CN101827825B (zh) 2012-11-21
PA8800401A1 (es) 2009-05-15
JP2011500708A (ja) 2011-01-06
BRPI0818337A2 (pt) 2017-05-23
US7772404B2 (en) 2010-08-10
ZA201002094B (en) 2011-11-30
RU2010119920A (ru) 2011-11-27
US20090124816A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
CY1115180T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
CO6361988A2 (es) Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)fenil]piperidina.
ECSP10010176A (es) Productos quimioterapéuticos cristalinos
ECSP10010175A (es) Productos quimioterapéuticos cristalinos
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida
DOP2010000113A (es) Productos quimioterapeuticos cristalinos
CR11386A (es) Productos quimioterapeuticos cristalinos
CL2008003709A1 (es) Uso de 4-[2-(4-metilfenil-sulfanil)fenil]piperidina y sus sales, para tratar una enfermedad seleccionada de retardo psicomotriz, depresion grave, ansiedad, enfermedad de parkinson, epilepsia, entre otras.
UY31407A1 (es) "productos quimioterapéuticos cristalinos"
RS51676B (en) USE OF AGOMELATIN FOR OBTAINING MEDICINES FOR SMITH-MAGENIS SYNDROME TREATMENT
UY28498A1 (es) Modificación de cristal de un derivado de n-fenil-2-pirimidinamina, procesos para su fabricación y su uso.
UY31988A (es) Compuestos de pirimidinilsulfonamida para utilizar en el tratamiento de una enfermedad mediada por quimiocina
CR7755A (es) Thiazolibifenilamidas